close
menu
close
menu
close
menu
close
menu
NHS pathology services are under pressure like never before. Demand for histopathology keeps climbing, driven by an ageing population, expanding screening programmes, and increasingly complex cancer diagnostics, while the workforce simply hasn't kept pace. The Royal College of Pathologists' 2025 Workforce Census puts numbers on the strain: nearly half of pathologists (47%) are aged 50 or over, raising concerns about a wave of retirements within the next decade,1 and 60% of consultants report working beyond their contracted hours in a typical week.2
And the stakes have never been higher, or more visible. The Government's National Cancer Plan for England, published in February 2026, sets a national standard for 98% of histopathology tests to be reported within 10 days, to be achieved by March 2029 and backed by £604 million of capital investment in digital diagnostics and £96 million to automate histopathology.3 Current performance sits a long way off: the Plan itself reports that average performance for cancer-pathway histopathology is just 68% within 10 days,4 and the 2026 Pathology Transformation Review found fewer than 10% of trusts achieving the 7- or 10-day turnaround targets.5 The Royal College of Pathologists has described the March 2029 target as "very ambitious given the current state of consultant staffing", noting that vacancies and planned retirements are likely to remain the biggest drag on turnaround times, even with digital pathology and AI tools in play.6
The College is right: integration doesn't create a single additional pathologist. But it determines how much of the capacity a trust does secure, whether in-house or external, actually reaches patients. When a trust buys external reporting and then loses days of it to couriers and re-keying, the scarcest resource in the system is being wasted at the point of maximum scarcity.
Extending pathology capacity beyond in-house teams is no longer a contingency plan for most trusts; it's an operational reality. The question isn't whether to work with an external reporting partner. It's how to do it without creating a whole new set of problems.
Trusts cannot close a 30-point performance gap by 2029 through in-house capacity alone; external reporting partners will inevitably be part of how the target is met. But that capacity only counts if the workflow connecting trust and partner is fast enough to keep pace. Every day a case spends in a courier van or a manual transcription queue is a day taken from the 10-day clock. NHS England now publishes turnaround performance for every trust, ICB, and region, so the gap between where a trust stands and where the Plan says it must be is on public record.7
For many trusts, the way outsourced reporting works today is quietly costing them the very efficiency they were trying to gain.
Most trusts sit on a technology estate that was never designed for this. Systems that struggle to talk to each other internally certainly can't easily talk to an external partner.
So when a trust needs to send cases out for reporting, everything falls back to manual processes:
Each step seems small, but together they're a real operational tax. In a typical send-away workflow, slides spend at least a day in transit, and courier schedules, weekends, and weather can stretch that considerably. Meanwhile, lab staff lose hours per day keying in request details and transcribing results back into the LIMS on return. Against a 10-day clock, that's a meaningful share of the window gone before a pathologist has seen a single slide: administrative hours labs can't spare, turnaround times inflated by transit and transcription rather than actual reporting, and quality risk at every manual touchpoint. In a service already stretched to its limits, that's capacity the NHS can't afford to waste.
"Integration, not scanning, is the stumbling block. Without end-to-end workflow integration, Trusts have a large digital slide archive instead of a complete digital workflow."
Professor Runjan Chetty, Chief Medical Officer, Diagnexia, writing in the Journal of Clinical Pathology on what the National Cancer Plan means for UK histopathology. Read full paper here.
At Diagnexia, the reason trusts come to us is our network of subspecialist pathologists. That expertise is the product. Integration is how that expertise reaches patients: if a case takes days to reach the right subspecialist and the report takes days more to get back into the LIMS, the expertise was never the bottleneck, and the trust never sees its full value. So we've built our service around a simple principle: the workflow matters as much as the reporting.
That's why we take an integration-first approach. Rather than bolting a manual process onto the side of a trust's existing systems, we connect directly with them, so that ordering, reporting, and image transfer happen electronically, automatically, and safely.
We build to established healthcare standards (HL7 and FHIR), with custom APIs where a trust's setup needs them, and over whichever connectivity approach fits the trust's infrastructure and security requirements. The trust's existing estate is the starting point, not an obstacle.
That approach is already live. At Northwest London Pathology, case details arrive through automated intake of manifests generated by their own systems (no manual re-keying), while whole slide images from their Philips Image Management System are integrated directly into our subspecialist network, with no couriers and no slide logistics. Completed reports return electronically rather than being transcribed by hand from PDFs, and turnaround has fallen from 6.2 to 2.6 calendar days — against a national standard of 10.
What this delivers:
A seamless workflow isn't a nice-to-have. It's what drives the efficiency gains that make quick turnaround possible, and it's a quality intervention in its own right. Every manual touchpoint in a paper-based workflow is an opportunity for error: a mis-keyed patient identifier, clinical details lost in transcription, a result attached to the wrong record. Integration doesn't make error impossible. It shifts risk from manual re-keying, where mistakes can go unnoticed, to controlled, auditable interfaces, where mapping is validated before go-live and failures are detectable and traceable. Data passes between systems as entered, results arrive structured rather than re-typed, and every case carries a complete electronic audit trail from order to report. Lab teams shift their time from re-keying data to verifying it: human oversight where it adds value, not manual labour where it adds risk.
We know that no two trusts are in the same place. Some are fully digitised with modern LIMS platforms; others are working with legacy systems and paper-heavy processes. An all-or-nothing integration project would be a barrier, not a solution.
So we don't do all-or-nothing. We implement integrations in phases: orders, results, WSI transfer, sequenced around where each trust is in its digital journey and, crucially, around what delivers immediate benefit first.
For one trust, that might mean starting with electronic results delivery, because manually entering returned reports is their biggest bottleneck. For another, it might be WSI transfer, because courier costs and transit delays are what's hurting turnaround. There's no fixed order, the roadmap is built around the trust's priorities, not ours.
Just as importantly, we do our utmost to minimise the work on the trust and LIMS vendor side by taking on maximum responsibility ourselves: the interface development, the mapping, the testing. What we typically need from a trust is bounded and predictable: a named LIMS/IT contact, project initiation with their LIMS vendor, sample messages from the existing system, access to a test environment, information governance sign-off, and a few hours of lab staff time for user acceptance testing before go-live. Trusts get the benefit of a connected workflow without needing to find capacity they don't have.
Three questions come up in every procurement conversation, so here are our answers up front. Diagnexia will never charge a customer for integration work: interface development, mapping, and testing on our side are part of the service, not a change-order revenue line. Trusts should budget for their own LIMS vendor's interface charges, which vary by supplier and contract; we help scope that conversation early so it's a known cost, not a surprise. And at contract end, the trust's data is the trust's data: results already sit in the trust's LIMS in structured form, and decommissioning the interface leaves nothing stranded on our side.
External and extended reporting capacity will remain an essential part of how the NHS keeps diagnostic services running, and keeps cancer pathways moving. But the model has to evolve. Manual, courier-and-paper workflows made sense when there was no alternative. There is one now, and with a 30-point gap to close in three years, there's no room in the pathway for avoidable delay.
Trusts evaluating reporting partners should ask not just "who will report my cases?" but "how will my cases get there and back, and what will it cost my team to make that happen?" The answer to that second question is where the real efficiency lives.
If your trust is looking for a true diagnostic partner and wants to understand what integration-first would look like in practice, whether you're fully digital or just starting out, we'd love to talk. Get in touch with the Diagnexia team, and we'll map out a phased approach built around what delivers value for you first.
1. Royal College of Pathologists, Workforce Census 2025. https://www.rcpath.org/profession/workforce-and-engagement/workforce-planning/workforce-census.html
2. Royal College of Pathologists, Workforce Census 2025 Spotlight 1: retirements and working patterns. https://www.rcpath.org/discover-pathology/news/workforce-census-2025-response-rate-retirements-working-patterns-and-sustainability-of-pathology-services.html
3. GOV.UK, National Cancer Plan for England (4 February 2026). https://www.gov.uk/government/publications/national-cancer-plan-for-england/the-national-cancer-plan-for-england-delivering-world-class-cancer-care-accessible-version
4. The King's Fund, analysis of the National Cancer Plan for England. https://www.kingsfund.org.uk/insight-and-analysis/blogs/national-cancer-plan-for-england
5. Institute of Biomedical Science, Pathology Transformation Review 2026. https://www.ibms.org/resource/pathology-transformation-report.html
6. Royal College of Pathologists, briefing on the National Cancer Plan for England. https://www.rcpath.org/discover-pathology/news/the-royal-college-of-pathologists-briefing-on-the-national-cancer-plan-for-england.html
7. NHS England, Histopathology Performance Data. https://www.england.nhs.uk/statistics/statistical-work-areas/diagnostics-waiting-times-and-activity/histopathology-performance-data/
NHS pathology services are under pressure like never before. Demand for histopathology keeps climbing, driven by an ageing population, expanding screening programmes, and increasingly complex cancer diagnostics, while the workforce simply hasn't kept pace. The Royal College of Pathologists' 2025 Workforce Census puts numbers on the strain: nearly half of pathologists (47%) are aged 50 or over, raising concerns about a wave of retirements within the next decade,1 and 60% of consultants report working beyond their contracted hours in a typical week.2
And the stakes have never been higher, or more visible. The Government's National Cancer Plan for England, published in February 2026, sets a national standard for 98% of histopathology tests to be reported within 10 days, to be achieved by March 2029 and backed by £604 million of capital investment in digital diagnostics and £96 million to automate histopathology.3 Current performance sits a long way off: the Plan itself reports that average performance for cancer-pathway histopathology is just 68% within 10 days,4 and the 2026 Pathology Transformation Review found fewer than 10% of trusts achieving the 7- or 10-day turnaround targets.5 The Royal College of Pathologists has described the March 2029 target as "very ambitious given the current state of consultant staffing", noting that vacancies and planned retirements are likely to remain the biggest drag on turnaround times, even with digital pathology and AI tools in play.6
The College is right: integration doesn't create a single additional pathologist. But it determines how much of the capacity a trust does secure, whether in-house or external, actually reaches patients. When a trust buys external reporting and then loses days of it to couriers and re-keying, the scarcest resource in the system is being wasted at the point of maximum scarcity.
Extending pathology capacity beyond in-house teams is no longer a contingency plan for most trusts; it's an operational reality. The question isn't whether to work with an external reporting partner. It's how to do it without creating a whole new set of problems.
Trusts cannot close a 30-point performance gap by 2029 through in-house capacity alone; external reporting partners will inevitably be part of how the target is met. But that capacity only counts if the workflow connecting trust and partner is fast enough to keep pace. Every day a case spends in a courier van or a manual transcription queue is a day taken from the 10-day clock. NHS England now publishes turnaround performance for every trust, ICB, and region, so the gap between where a trust stands and where the Plan says it must be is on public record.7
For many trusts, the way outsourced reporting works today is quietly costing them the very efficiency they were trying to gain.
Most trusts sit on a technology estate that was never designed for this. Systems that struggle to talk to each other internally certainly can't easily talk to an external partner.
So when a trust needs to send cases out for reporting, everything falls back to manual processes:
Each step seems small, but together they're a real operational tax. In a typical send-away workflow, slides spend at least a day in transit, and courier schedules, weekends, and weather can stretch that considerably. Meanwhile, lab staff lose hours per day keying in request details and transcribing results back into the LIMS on return. Against a 10-day clock, that's a meaningful share of the window gone before a pathologist has seen a single slide: administrative hours labs can't spare, turnaround times inflated by transit and transcription rather than actual reporting, and quality risk at every manual touchpoint. In a service already stretched to its limits, that's capacity the NHS can't afford to waste.
"Integration, not scanning, is the stumbling block. Without end-to-end workflow integration, Trusts have a large digital slide archive instead of a complete digital workflow."
Professor Runjan Chetty, Chief Medical Officer, Diagnexia, writing in the Journal of Clinical Pathology on what the National Cancer Plan means for UK histopathology. Read full paper here.
At Diagnexia, the reason trusts come to us is our network of subspecialist pathologists. That expertise is the product. Integration is how that expertise reaches patients: if a case takes days to reach the right subspecialist and the report takes days more to get back into the LIMS, the expertise was never the bottleneck, and the trust never sees its full value. So we've built our service around a simple principle: the workflow matters as much as the reporting.
That's why we take an integration-first approach. Rather than bolting a manual process onto the side of a trust's existing systems, we connect directly with them, so that ordering, reporting, and image transfer happen electronically, automatically, and safely.
We build to established healthcare standards (HL7 and FHIR), with custom APIs where a trust's setup needs them, and over whichever connectivity approach fits the trust's infrastructure and security requirements. The trust's existing estate is the starting point, not an obstacle.
That approach is already live. At Northwest London Pathology, case details arrive through automated intake of manifests generated by their own systems (no manual re-keying), while whole slide images from their Philips Image Management System are integrated directly into our subspecialist network, with no couriers and no slide logistics. Completed reports return electronically rather than being transcribed by hand from PDFs, and turnaround has fallen from 6.2 to 2.6 calendar days — against a national standard of 10.
What this delivers:
A seamless workflow isn't a nice-to-have. It's what drives the efficiency gains that make quick turnaround possible, and it's a quality intervention in its own right. Every manual touchpoint in a paper-based workflow is an opportunity for error: a mis-keyed patient identifier, clinical details lost in transcription, a result attached to the wrong record. Integration doesn't make error impossible. It shifts risk from manual re-keying, where mistakes can go unnoticed, to controlled, auditable interfaces, where mapping is validated before go-live and failures are detectable and traceable. Data passes between systems as entered, results arrive structured rather than re-typed, and every case carries a complete electronic audit trail from order to report. Lab teams shift their time from re-keying data to verifying it: human oversight where it adds value, not manual labour where it adds risk.
We know that no two trusts are in the same place. Some are fully digitised with modern LIMS platforms; others are working with legacy systems and paper-heavy processes. An all-or-nothing integration project would be a barrier, not a solution.
So we don't do all-or-nothing. We implement integrations in phases: orders, results, WSI transfer, sequenced around where each trust is in its digital journey and, crucially, around what delivers immediate benefit first.
For one trust, that might mean starting with electronic results delivery, because manually entering returned reports is their biggest bottleneck. For another, it might be WSI transfer, because courier costs and transit delays are what's hurting turnaround. There's no fixed order, the roadmap is built around the trust's priorities, not ours.
Just as importantly, we do our utmost to minimise the work on the trust and LIMS vendor side by taking on maximum responsibility ourselves: the interface development, the mapping, the testing. What we typically need from a trust is bounded and predictable: a named LIMS/IT contact, project initiation with their LIMS vendor, sample messages from the existing system, access to a test environment, information governance sign-off, and a few hours of lab staff time for user acceptance testing before go-live. Trusts get the benefit of a connected workflow without needing to find capacity they don't have.
Three questions come up in every procurement conversation, so here are our answers up front. Diagnexia will never charge a customer for integration work: interface development, mapping, and testing on our side are part of the service, not a change-order revenue line. Trusts should budget for their own LIMS vendor's interface charges, which vary by supplier and contract; we help scope that conversation early so it's a known cost, not a surprise. And at contract end, the trust's data is the trust's data: results already sit in the trust's LIMS in structured form, and decommissioning the interface leaves nothing stranded on our side.
External and extended reporting capacity will remain an essential part of how the NHS keeps diagnostic services running, and keeps cancer pathways moving. But the model has to evolve. Manual, courier-and-paper workflows made sense when there was no alternative. There is one now, and with a 30-point gap to close in three years, there's no room in the pathway for avoidable delay.
Trusts evaluating reporting partners should ask not just "who will report my cases?" but "how will my cases get there and back, and what will it cost my team to make that happen?" The answer to that second question is where the real efficiency lives.
If your trust is looking for a true diagnostic partner and wants to understand what integration-first would look like in practice, whether you're fully digital or just starting out, we'd love to talk. Get in touch with the Diagnexia team, and we'll map out a phased approach built around what delivers value for you first.
1. Royal College of Pathologists, Workforce Census 2025. https://www.rcpath.org/profession/workforce-and-engagement/workforce-planning/workforce-census.html
2. Royal College of Pathologists, Workforce Census 2025 Spotlight 1: retirements and working patterns. https://www.rcpath.org/discover-pathology/news/workforce-census-2025-response-rate-retirements-working-patterns-and-sustainability-of-pathology-services.html
3. GOV.UK, National Cancer Plan for England (4 February 2026). https://www.gov.uk/government/publications/national-cancer-plan-for-england/the-national-cancer-plan-for-england-delivering-world-class-cancer-care-accessible-version
4. The King's Fund, analysis of the National Cancer Plan for England. https://www.kingsfund.org.uk/insight-and-analysis/blogs/national-cancer-plan-for-england
5. Institute of Biomedical Science, Pathology Transformation Review 2026. https://www.ibms.org/resource/pathology-transformation-report.html
6. Royal College of Pathologists, briefing on the National Cancer Plan for England. https://www.rcpath.org/discover-pathology/news/the-royal-college-of-pathologists-briefing-on-the-national-cancer-plan-for-england.html
7. NHS England, Histopathology Performance Data. https://www.england.nhs.uk/statistics/statistical-work-areas/diagnostics-waiting-times-and-activity/histopathology-performance-data/
